Moderna's Ambitious Pivot: Why Its Science Day Vision Outruns Today's Valuation

Related Articles

Enphase Energy's AI Hype Outruns Its Solar Reality

3 months ago

Bloom Energy's AI Momentum Outruns Chambers' $3M Sale, Yet Valuation Warning Remains

2 months ago

Can Moderna Rebound Beyond Its COVID-19 Legacy

5 months ago

Tesla's AI Vision Collides with a Crushing Valuation and Cash Burn

2 months ago

Category

You may also like

Stock News•3 weeks ago

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

Moderna rose 8% to $147.37 in Friday morning trading, a sharp single-name move while biotech peers and broader U.S. equities were quiet or only modestly higher.

MRNA

Share

Stock News•1 months ago

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

Moderna shares have pulled back from recent highs after jumping over 5x, but a new clinical milestone could boost prospects. The mRNA leader's latest data may support further upside if momentum contin...

MRNA

Share

Stock News•2 months ago

Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now

Moderna faces weak near-term demand but guides up to 10% revenue growth in 2026, driven by a diversified pipeline. A Phase 3 norovirus setback underscores execution risk, making valuation hinge on pip...

MRNA

Share